查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1808362

发炎性肠道疾病治疗市场按治疗类型、给药途径、製剂类型、用途、最终用户、分销管道和患者类型划分 - 2025-2030 年全球预测

Inflammatory Bowel Disease Treatment Market by Treatment Type, Route Of Administration, Formulation Type, Application, End-User, Distribution Channel, Patient Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

发炎性肠道疾病治疗市场预计在 2024 年达到 200.1 亿美元，在 2025 年成长至 209.5 亿美元，复合年增长率为 4.83%，到 2030 年将达到 265.6 亿美元。

主要市场统计数据
基准年2024年 200.1亿美元
预计2025年 209.5亿美元
预测年份 2030 265.6亿美元
复合年增长率（%） 4.83%

全面介绍影响发炎性肠道疾病治疗生态系统的新兴动态和关键驱动因素

发炎性肠道疾病涵盖频谱复杂的慢性胃肠道疾病，其特征是发炎反覆发作、患者发病率高以及迫切需要更有效的治疗方法。近年来，先进生物製药、精准医疗方法和不断扩展的真实世界数据的融合，改变了我们对疾病病理生理学和治疗模式的理解。随着临床试验越来越多地纳入分子亚型和创新终点，从药物开发商到医疗保健系统的相关人员正在重新调整其策略，以利用新的机会。

在发炎性肠道疾病不断发展的领域中，变革性变化重新定义了研究、治疗方法和患者结果

在标靶免疫学和再生医学突破的推动下，发炎性肠道疾病领域正在经历根本性变革时期。发炎性肠道疾病市场历来以小分子药物和皮质类固醇为主，如今正转向更安全、更有效、生物目标，例如整合素受体拮抗剂和白细胞介素抑制剂。同时，基因治疗载体、微生物组修饰剂和干细胞移植等先进疗法正进入后期研发阶段，可望恢復黏膜完整性和免疫稳态，进而达到持久缓解。

评估 2025 年美国关税对 IBD 治疗创新和市场准入的累积影响

预计2025年美国关税政策的调整将对发炎性肠道疾病治疗的供应链和成本结构产生深远影响。关键原料和原料药的进口关税上调，可能迫使製造商重新评估筹资策略或承担额外成本，可能影响价格谈判和报销谈判。因此，决策者应密切关注政策发展，并探索替代原材料采购和本地製造合作伙伴关係，以降低成本上涨。

深度细分洞察揭示治疗方式、给药途径、製剂类型、应用、最终用户和患者群体

发炎性肠道疾病治疗市场从多个角度进行分析，以发现重大机会和未满足的需求。治疗类型涵盖基础小分子药物，例如氨基水杨酸盐、皮质类固醇和免疫抑制剂，以及尖端生物製药製剂，例如肿瘤坏死因子抑制剂、白细胞介素阻断剂和整合素受体拮抗剂。先进的治疗方法正变得越来越多样化，包括旨在重置免疫调节的基因疗法、旨在恢復肠道菌群平衡的微生物组调节药物，以及专注于再生受损肠道组织的干细胞疗法。对于难治性病例，外科手术介入仍然至关重要，从复杂解剖挑战的切除术到切除术和狭窄成形术。

区域洞察重点介绍美洲、欧洲、中东和非洲地区以及亚太地区 IBD 药物的成长动力和病患可及性趋势

不同地区的发炎性肠道疾病 (IBD) 治疗受不同因素的影响。在美洲，强大的医疗基础设施和完善的报销框架正在促进新型疗法的快速应用。病患权益团体和临床网络进一步提高了人们对IBD的认识，并支持早期诊断和坚持长期治疗方法。然而，新的挑战包括支付方对生物製药高成本的监督，以及需要透过全面的病患登记来证明其在现实世界中的价值。

策略性公司概况和竞争定位突显发炎性肠道疾病治疗领域的创新途径和市场领导地位

领先的製药和生物技术公司正在推行多元化策略，以巩固其在发炎性肠道疾病领域的地位。现有企业正在透过新一代抗体构建体和生物相似药开发项目增强其生技药品产品组合，而新兴创新企业则利用先进的治疗平台，并携手合作，共同开发基因治疗候选药物和基于微生物的干预措施。大型公司与敏捷的生物技术公司之间的合作，利用双方在製程开发和临床营运方面的互补专业知识，加速后期临床试验。

可行的策略建议，以推动永续成长、改善患者治疗效果并促进 IBD 主要相关人员之间的合作

产业领导者应优先投资针对潜在疾病机制的差异化治疗方法，例如标靶特异性较高、疗效持久的下一代生技药品。同时，将数位健康解决方案纳入临床试验方案和上市后监测，可以促进以患者为中心的参与，并产生真实世界证据以支持报销谈判。此外，促进多方相关利益者合作，包括与学术研究中心、病患权益组织和合约研究组织建立伙伴关係，可以加速转化研究，并简化与监管机构的互动。

结合多源资料收集、定性和定量分析以及严格检验过程的调查方法

该研究整合了多种资讯方法，将广泛的二手资料审查与透过深入访谈行业高管、临床医生和付款人收集的一手资讯相结合。二手资料研究涵盖同行评审出版物、监管备案文件、临床试验资料库和行业白皮书，旨在对治疗机制、竞争格局和市场准入动态建立基础理解。一手数据研究则包括与跨区域意见领袖进行结构化讨论，以深入了解临床应用驱动因素和患者管理挑战的微妙观点。

综合结论总结了不断发展的发炎性肠道疾病治疗市场中相关人员的主要发现和未来前景

本执行摘要全面分析了影响发炎性肠道疾病治疗市场的关键趋势，涵盖从新型治疗层级和先进治疗方法到预期关税变化的策略影响。細項分析揭示了产品差异化的关键途径，包括治疗类型、给药途径、製剂形式和患者群体。区域洞察突显了多样化的成长动力，涵盖美洲成熟的报销格局，欧洲、中东和非洲 (EMEA) 的监管协调工作，以及亚太地区激增的需求。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 微创治疗对于提高 IBD 患者的依从性越来越重要
  • 个人化医疗方法在发炎性肠道疾病治疗的应用日益增多
  • 调节肠道菌丛作为 IBD 的新治疗策略正受到关注
  • 扩大小分子药物研发管线，为发炎性肠道疾病 (IBD) 提供替代疗法
  • 标靶药物输送系统的进展提高了发炎性肠道疾病 (IBD) 治疗的有效性
  • 整合数位健康技术，远端监控 IBD 患者
  • 过渡到联合治疗以改善发炎性肠道疾病的疗效
  • 认知度的提高和早期诊断推动了对创新 IBD 治疗的需求
  • 监管部门的核准加速了下一代 IBD 药物的上市
  • 生物製剂和生物相似药的出现正在改变全球 IBD 治疗方案

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

8. 发炎性肠道疾病治疗市场（依治疗类型）

  • 先进治疗
    • 基因治疗
    • 微生物组调变器
    • 干细胞疗法
  • 生物製药
    • 整合素受体拮抗剂
    • 白细胞介素抑制剂
    • TNF抑制剂
  • 小分子药物
    • 氨基水杨酸盐
    • 皮质类固醇
    • 免疫抑制剂
  • 外科手术
    • 造口
    • 切除
    • 狭窄成形术

9. 发炎性肠道疾病治疗市场（依给药途径）

  • 注射
    • 静脉
    • 皮下
  • 口服
  • 直肠

10. 发炎性肠道疾病治疗市场（依处方类型）

  • 液体製剂
    • 口服溶液
    • 暂停
  • 肠外製剂
  • 固态剂型
    • 咀嚼片
    • 缓释片

第 11 章炎症性肠道疾病治疗市场：按应用

  • 克隆氏症
  • 非典型结肠炎
  • 溃疡性大肠炎

12. 发炎性肠道疾病治疗市场（依最终使用者）

  • 诊所
  • 居家照护环境
  • 医院

13. 发炎性肠道疾病治疗市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

14. 发炎性肠道疾病治疗市场（依患者型态）

  • 成年人口
  • 老年人口
  • 儿科族群

15.美洲发炎性肠道疾病治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

16. 欧洲、中东和非洲发炎性肠道疾病治疗市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

17. 亚太地区发炎性肠道疾病治疗市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十八章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • AbbVie Inc.
    • Abivax
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Cipla Limited
    • Eli Lilly and Company
    • Entera Bio Ltd.
    • FutureGen Biopharmaceutical（Beijing）Co., Ltd.
    • GlaxoSmithKline PLC
    • Ironwood Pharmaceuticals, Inc.
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Morphic Therapeutic, Inc.
    • Nestle SA
    • OPKO Health, Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharma Limited
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • TScan Therapeutics, Inc.
    • UCB SA
    • Viatris Inc.
    • Zealand Pharma A/S

第十九章 研究人工智慧

第20章 研究统计

第21章 研究联络人

第22章 研究报导

第23章 附录

Product Code: MRR-563BF1FCFF1E

The Inflammatory Bowel Disease Treatment Market was valued at USD 20.01 billion in 2024 and is projected to grow to USD 20.95 billion in 2025, with a CAGR of 4.83%, reaching USD 26.56 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 20.01 billion
Estimated Year [2025] USD 20.95 billion
Forecast Year [2030] USD 26.56 billion
CAGR (%) 4.83%

A Comprehensive Introduction to Emerging Dynamics and Critical Drivers Shaping the Inflammatory Bowel Disease Treatment Ecosystem

Inflammatory bowel disease encompasses a complex spectrum of chronic gastrointestinal disorders characterized by relapsing inflammation, significant patient morbidity, and an urgent need for more effective therapies. In recent years, the convergence of advanced biologic agents, precision medicine approaches, and expanding real-world data has transformed our understanding of disease pathophysiology and treatment paradigms. As clinical trials increasingly embrace molecular subtyping and innovative endpoints, stakeholders from pharmaceutical developers to healthcare systems are realigning their strategies to capitalize on emerging opportunities.

Furthermore, dynamic shifts in patient demographics, regulatory frameworks, and reimbursement landscapes are elevating the demand for differentiated therapeutic solutions. Healthcare providers are seeking treatments that offer sustained remission with minimized safety concerns, while payers are scrutinizing value propositions to manage the economic burden of chronic immune-mediated diseases. As a result, industry participants are deploying multidisciplinary research and forging cross-sector collaborations to accelerate the development of pioneering modalities that aim to redefine standards of care in inflammatory bowel disease.

Transformational Shifts Redefining Research, Treatment Modalities, and Patient Outcomes in the Evolving Inflammatory Bowel Disease Landscape

The inflammatory bowel disease landscape has undergone fundamental transformations driven by breakthroughs in targeted immunology and regenerative medicine. Historically dominated by small molecule drugs and corticosteroids, the market has shifted toward precision-targeted biologics such as integrin receptor antagonists and interleukin inhibitors, which offer superior safety and efficacy profiles. Concurrently, advanced therapies-including gene therapy vectors, microbiome modulators, and stem cell transplantation-are entering late-stage development, promising durable remission through restoration of mucosal integrity and immune homeostasis.

Moreover, digital health innovations and remote monitoring tools are enabling real-time disease management and empowering patients to actively participate in therapy regimens. Advances in telemedicine platforms are streamlining follow-up care, reducing hospitalizations, and improving adherence. In parallel, evolving regulatory pathways now accommodate breakthrough designations and adaptive trial designs, expediting the translation of laboratory discoveries into clinical interventions. Together, these shifts are redefining competitive dynamics and creating fertile ground for next-generation therapies that target the root causes of inflammatory bowel disease.

Assessing the Projected Cumulative Impact of 2025 United States Tariffs on Therapeutic Innovation and Market Accessibility in IBD Care

Anticipated adjustments in United States tariff policies for 2025 carry far-reaching implications for the inflammatory bowel disease therapy supply chain and cost structures. Increased import duties on key raw materials and active pharmaceutical ingredients may compel manufacturers to reassess sourcing strategies or absorb additional expenses, potentially affecting pricing negotiations and reimbursement discussions. Consequently, decision makers must monitor policy developments closely and explore alternative materials procurement or localized production partnerships to mitigate cost escalations.

Furthermore, tariff-induced pressures could accelerate interest in domestic biomanufacturing capabilities, spurring investments in flexible facilities and contract development organizations to localize critical manufacturing processes. Such a shift would not only buffer companies against external trade fluctuations but also enhance supply chain resilience. At the same time, collaborations with regulatory bodies and industry coalitions will be essential to navigate potential compliance hurdles and secure timely approvals. By proactively addressing these tariff dynamics, stakeholders can safeguard market access and maintain momentum in bringing innovative IBD therapies to patients.

Deep Dive into Segmentation Insights Revealing Treatment Modalities, Administration Routes, Formulation Types, Applications, End-Users, and Patient Demographics

The inflammatory bowel disease treatment market is dissected across multiple dimensions to reveal critical opportunities and unmet needs. Based on treatment type, research efforts extend from foundational small molecule drugs such as aminosalicylates, corticosteroids, and immunosuppressants to cutting-edge biologic classes including tumor necrosis factor inhibitors, interleukin blockers, and integrin receptor antagonists. Advanced therapies further diversify the landscape through gene therapy constructs designed to reset immune regulation, microbiome modulators aiming to restore gut flora balance, and stem cell therapies focused on regenerating damaged intestinal tissue. Surgical interventions remain integral for refractory cases, with procedures ranging from ostomy creation to resections and strictureplasties tailored to complex anatomical challenges.

In addition, administration route segmentation highlights the strategic relevance of injectable formulations delivered intravenously or subcutaneously, complemented by patient-preferred oral and rectal therapies that foster adherence. Formulation type analysis underscores the distinction between liquid formulations, such as oral solutions and suspensions, versus solid dosage forms including chewable and extended release tablets, alongside specialized parenteral preparations. Treatment applications concentrate on Crohn's disease, indeterminate colitis, and ulcerative colitis, each presenting unique pathophysiology and therapeutic endpoints. Moreover, end-user settings span traditional hospital environments, specialized clinics, and increasingly vital home care scenarios that support self-administration. Distribution channels cut across hospital pharmacies, online platforms, and retail outlets to optimize patient access. Finally, patient type considerations differentiate adult, geriatric, and pediatric populations, ensuring that product development and care models address distinct safety, dosing, and compliance factors across life stages.

Regional Insights Unveiling Distinct Growth Drivers and Patient Access Dynamics across the Americas, EMEA, and Asia-Pacific in IBD Therapeutics

Regional dynamics shape the inflammatory bowel disease treatment landscape in distinct ways. In the Americas, robust healthcare infrastructure and established reimbursement frameworks facilitate rapid adoption of novel therapies. Patient advocacy groups and clinical networks further drive awareness, supporting early diagnosis and adherence to long-term treatment regimens. However, emerging challenges include payer scrutiny of high-cost biologics and the imperative to demonstrate real-world value through comprehensive patient registries.

In Europe, the Middle East, and Africa, a mosaic of regulatory environments influences market entry strategies. Harmonization efforts across the European Union streamline approval pathways, whereas variable reimbursement policies in the Middle East and Africa necessitate adaptive pricing models. Local manufacturing partnerships and public-private initiatives are increasingly critical to improve therapy availability and address regional disease burdens. Across Asia-Pacific, escalating IBD incidence, bolstered by lifestyle shifts and urbanization, is prompting governments to prioritize chronic disease management. Incentives for domestic biotech innovation and strategic licensing agreements are propelling new entrants into this high-growth arena, while generics and biosimilars play an essential role in expanding patient access.

Strategic Company Profiles and Competitive Positioning Highlighting Innovation Pathways and Market Leadership in Inflammatory Bowel Disease Treatment

Leading pharmaceutical and biotechnology companies are pursuing diverse strategies to secure their positions in the inflammatory bowel disease arena. Established players are enhancing their biologics portfolios with next-generation antibody constructs and biosimilar development programs. Meanwhile, emerging innovators are capitalizing on advanced therapy platforms, forging alliances to co-develop gene therapy candidates and microbiome-based interventions. Collaborative ventures between large-cap firms and nimble biotechs are accelerating late-stage trials, leveraging complementary expertise in process development and clinical operations.

Competitive positioning is also influenced by robust intellectual property protection and strategic patent litigation, as companies seek to extend exclusivity periods for high-value assets. In parallel, royalty monetization agreements and divestitures of non-core assets are optimizing balance sheets, enabling reinvestment in high-potential pipelines. As regulatory agencies exhibit greater flexibility through accelerated pathways and conditional approvals, organizations equipped with adaptive clinical trial designs and real-world evidence capabilities will gain a decisive advantage. Overall, the interplay of M&A activity, co-development partnerships, and innovation-driven collaboration is reshaping the competitive terrain.

Actionable Strategic Recommendations to Drive Sustainable Growth, Enhance Patient Outcomes, and Foster Collaboration among Key Stakeholders in IBD

Industry leaders should prioritize investment in differentiated modalities that address underlying disease mechanisms, such as next-generation biologics with enhanced targeting specificity and durable response profiles. In parallel, integrating digital health solutions into clinical trial protocols and post-market surveillance can foster patient-centric engagement and generate real-world evidence to support reimbursement negotiations. Furthermore, cultivating multi-stakeholder collaborations-including alliances with academic research centers, patient advocacy groups, and contract development organizations-will accelerate translational research and streamline regulatory interactions.

Moreover, supply chain resilience should be fortified by diversifying manufacturing footprints and exploring regional production partnerships to mitigate tariff impacts and logistical disruptions. Organizations are encouraged to adopt modular facility designs and flexible contract manufacturing strategies to adapt to evolving demand patterns. Lastly, a concerted focus on emerging markets-supported by localized value demonstration and tiered pricing frameworks-will unlock high-growth opportunities while advancing equitable access to transformative therapies.

Robust Research Methodology Combining Multi-Source Data Collection, Qualitative and Quantitative Analyses, and Rigorous Validation Processes

This research integrates a multi-source approach, combining extensive secondary data review with primary insights gathered through in-depth interviews with industry executives, clinicians, and payers. Secondary research encompassed peer-reviewed publications, regulatory filings, clinical trial databases, and industry white papers to establish a robust foundational understanding of therapeutic mechanisms, competitive landscapes, and market access dynamics. Primary engagements involved structured discussions with opinion leaders across geographies, uncovering nuanced perspectives on clinical adoption drivers and patient management challenges.

Quantitative analysis was conducted using proprietary data models that triangulate findings across independent datasets, ensuring rigorous validation of thematic conclusions. Qualitative thematic coding was applied to interview transcripts to identify recurring trends, unmet clinical needs, and strategic imperatives. Iterative validation workshops with domain experts further refined key insights and resolved information gaps. Together, these methodologies provide a comprehensive, reliable, and actionable framework for stakeholders navigating the inflammatory bowel disease treatment arena.

Comprehensive Conclusion Synthesizing Key Findings and Future Outlook for Stakeholders in the Evolving Inflammatory Bowel Disease Treatment Market

This executive summary has synthesized pivotal developments shaping the inflammatory bowel disease treatment market, from emerging therapeutic classes and advanced modalities to the strategic implications of anticipated tariff changes. Segmentation analysis has illuminated critical pathways for product differentiation across treatment types, administration routes, formulation formats, and patient demographics. Regional insights underscore the multiplicity of growth drivers-from mature reimbursement landscapes in the Americas to regulatory harmonization efforts in EMEA and surging demand trajectories in Asia-Pacific.

Competitive intelligence reveals that innovation convergence, strategic partnerships, and agile manufacturing approaches will determine market leadership moving forward. Actionable recommendations emphasize the importance of targeted investment in next-generation therapies, digital health integration, supply chain resilience, and market-specific access strategies. As stakeholders chart their strategies for 2025 and beyond, a proactive, evidence-based approach will be essential to unlocking value, enhancing patient outcomes, and sustaining long-term growth in this dynamic and high-stakes therapeutic domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Growing emphasis on minimally invasive therapies for better patient compliance in IBD
  • 5.2. Rising adoption of personalized medicine approaches in managing inflammatory bowel disease
  • 5.3. Increased focus on gut microbiome modulation as a novel IBD therapeutic strategy
  • 5.4. Expanding pipeline of small molecule drugs offering alternative treatments for IBD
  • 5.5. Advancements in targeted drug delivery systems improving efficacy in IBD therapies
  • 5.6. Integration of digital health technologies for remote monitoring of IBD patients
  • 5.7. Shift towards combination therapies to enhance treatment outcomes in inflammatory bowel disease
  • 5.8. Surge in awareness and early diagnosis driving demand for innovative IBD treatments
  • 5.9. Impact of regulatory approvals accelerating launch of next-generation IBD therapies
  • 5.10. Emergence of biologics and biosimilars transforming IBD treatment options globally

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Inflammatory Bowel Disease Treatment Market, by Treatment Type

  • 8.1. Introduction
  • 8.2. Advanced Therapies
    • 8.2.1. Gene Therapy
    • 8.2.2. Microbiome Modulators
    • 8.2.3. Stem Cell Therapy
  • 8.3. Biologics
    • 8.3.1. Integrin Receptor Antagonists
    • 8.3.2. Interleukin Inhibitors
    • 8.3.3. TNF Inhibitors
  • 8.4. Small Molecule Drugs
    • 8.4.1. Aminosalicylates
    • 8.4.2. Corticosteroids
    • 8.4.3. Immunosuppressants
  • 8.5. Surgical Procedures
    • 8.5.1. Ostomy
    • 8.5.2. Resection
    • 8.5.3. Strictureplasty

9. Inflammatory Bowel Disease Treatment Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Injectable
    • 9.2.1. Intravenous
    • 9.2.2. Subcutaneous
  • 9.3. Oral
  • 9.4. Rectal

10. Inflammatory Bowel Disease Treatment Market, by Formulation Type

  • 10.1. Introduction
  • 10.2. Liquid Formulations
    • 10.2.1. Oral Solutions
    • 10.2.2. Suspensions
  • 10.3. Parenteral Preparations
  • 10.4. Solid Dosage Forms
    • 10.4.1. Chewable Tablets
    • 10.4.2. Extended Release Tablets

11. Inflammatory Bowel Disease Treatment Market, by Application

  • 11.1. Introduction
  • 11.2. Crohns Disease
  • 11.3. Indeterminate Colitis
  • 11.4. Ulcerative Colitis

12. Inflammatory Bowel Disease Treatment Market, by End-User

  • 12.1. Introduction
  • 12.2. Clinics
  • 12.3. Home Care Settings
  • 12.4. Hospitals

13. Inflammatory Bowel Disease Treatment Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Hospital Pharmacies
  • 13.3. Online Pharmacies
  • 13.4. Retail Pharmacies

14. Inflammatory Bowel Disease Treatment Market, by Patient Type

  • 14.1. Introduction
  • 14.2. Adult Population
  • 14.3. Geriatric Population
  • 14.4. Pediatric Population

15. Americas Inflammatory Bowel Disease Treatment Market

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. Argentina

16. Europe, Middle East & Africa Inflammatory Bowel Disease Treatment Market

  • 16.1. Introduction
  • 16.2. United Kingdom
  • 16.3. Germany
  • 16.4. France
  • 16.5. Russia
  • 16.6. Italy
  • 16.7. Spain
  • 16.8. United Arab Emirates
  • 16.9. Saudi Arabia
  • 16.10. South Africa
  • 16.11. Denmark
  • 16.12. Netherlands
  • 16.13. Qatar
  • 16.14. Finland
  • 16.15. Sweden
  • 16.16. Nigeria
  • 16.17. Egypt
  • 16.18. Turkey
  • 16.19. Israel
  • 16.20. Norway
  • 16.21. Poland
  • 16.22. Switzerland

17. Asia-Pacific Inflammatory Bowel Disease Treatment Market

  • 17.1. Introduction
  • 17.2. China
  • 17.3. India
  • 17.4. Japan
  • 17.5. Australia
  • 17.6. South Korea
  • 17.7. Indonesia
  • 17.8. Thailand
  • 17.9. Philippines
  • 17.10. Malaysia
  • 17.11. Singapore
  • 17.12. Vietnam
  • 17.13. Taiwan

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Abbott Laboratories
    • 18.3.2. AbbVie Inc.
    • 18.3.3. Abivax
    • 18.3.4. Amgen Inc.
    • 18.3.5. Bristol-Myers Squibb Company
    • 18.3.6. Cipla Limited
    • 18.3.7. Eli Lilly and Company
    • 18.3.8. Entera Bio Ltd.
    • 18.3.9. FutureGen Biopharmaceutical (Beijing) Co., Ltd.
    • 18.3.10. GlaxoSmithKline PLC
    • 18.3.11. Ironwood Pharmaceuticals, Inc.
    • 18.3.12. Johnson & Johnson Services, Inc.
    • 18.3.13. Merck & Co., Inc.
    • 18.3.14. Morphic Therapeutic, Inc.
    • 18.3.15. Nestle S.A.
    • 18.3.16. OPKO Health, Inc.
    • 18.3.17. Pfizer Inc.
    • 18.3.18. Sanofi SA
    • 18.3.19. Sun Pharma Limited
    • 18.3.20. Takeda Pharmaceutical Company Limited
    • 18.3.21. Teva Pharmaceutical Industries Ltd.
    • 18.3.22. TScan Therapeutics, Inc.
    • 18.3.23. UCB S.A.
    • 18.3.24. Viatris Inc.
    • 18.3.25. Zealand Pharma A/S

19. ResearchAI

20. ResearchStatistics

21. ResearchContacts

22. ResearchArticles

23. Appendix

LIST OF FIGURES

  • FIGURE 1. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 22. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 26. ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 29. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: RESEARCHAI
  • FIGURE 30. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: RESEARCHSTATISTICS
  • FIGURE 31. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: RESEARCHCONTACTS
  • FIGURE 32. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY MICROBIOME MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY MICROBIOME MODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTEGRIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTEGRIN RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY OSTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY OSTOMY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RESECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RESECTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STRICTUREPLASTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STRICTUREPLASTY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RECTAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL PREPARATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PARENTERAL PREPARATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CHEWABLE TABLETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHNS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CROHNS DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INDETERMINATE COLITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADULT POPULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADULT POPULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GERIATRIC POPULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY GERIATRIC POPULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC POPULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PEDIATRIC POPULATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 139. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 141. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 143. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 167. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 168. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED STATES INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 177. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 179. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 189. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 190. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 191. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 193. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 194. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 195. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 196. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 197. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 199. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 201. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 203. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. CANADA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 209. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 210. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 211. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 212. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 213. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 214. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 215. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 217. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 218. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 219. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 222. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 223. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 224. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 225. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 227. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 228. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 229. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 231. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 235. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 236. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 237. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 239. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 241. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 243. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 245. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 246. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 247. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 250. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 251. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 252. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 253. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 255. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 256. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 257. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 259. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. BRAZIL INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 264. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ADVANCED THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 265. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 266. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 267. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2024 (USD MILLION)
  • TABLE 268. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SMALL MOLECULE DRUGS, 2025-2030 (USD MILLION)
  • TABLE 269. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2024 (USD MILLION)
  • TABLE 270. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2025-2030 (USD MILLION)
  • TABLE 271. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 273. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 274. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
  • TABLE 275. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY FORMULATION TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 278. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY LIQUID FORMULATIONS, 2025-2030 (USD MILLION)
  • TABLE 279. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 280. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2030 (USD MILLION)
  • TABLE 281. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 283. ARGENTINA INFLAMMATORY BOWEL DISEASE TREATMENT MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)

TABLE 2